 Co-Diagnostics Inc NASDAQ:CODX posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further advance its Co-Dx PCR Home testing platform for infectious diseases. As of September 30, 2022, the Salt Lake City, Utah-based molecular diagnostics company, had cash, equivalents, and marketable securities of 86.5 million. 